Biomea Fusion Inc Cash Flow Conversion Efficiency
Biomea Fusion Inc cash flow conversion efficiency. Based on the latest financial reports, Biomea Fusion Inc (BMEA) has a cash flow conversion efficiency ratio of -0.623x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-11.67 Million) by net assets ($18.72 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Biomea Fusion Inc (2019–2025)
Cash flow conversion efficiency of Biomea Fusion Inc from 2019 to 2025. This chart illustrates how Biomea Fusion Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View BMEA stock price for real-time trading data and today's change.
Biomea Fusion Inc Cash Flow Conversion Ratio Explained
Biomea Fusion Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Biomea Fusion Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biomea Fusion Inc ranked by their cash flow conversion efficiency. Also see Biomea Fusion Inc (BMEA) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hofseth Biocare ASA
OL:HBC
|
0.167x |
|
InkTec Co. Ltd
KQ:049550
|
0.033x |
|
Walkabout Resources Ltd
AU:WKT
|
-0.073x |
|
Sigong Tech Co. Ltd
KQ:020710
|
-0.056x |
|
Beijing JIAYU Door Window Curtain
SHE:300117
|
-0.023x |
|
Iskandar Waterfront City Bhd
KLSE:1589
|
0.015x |
|
Immutep Limited
F:YP1A
|
-0.119x |
|
PEH Wertpapier AG
F:PEH
|
0.048x |
Annual Cash Flow Conversion Efficiency for Biomea Fusion Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Biomea Fusion Inc from 2019 to 2025. Review financial flexibility index of Biomea Fusion Inc to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $29.55 Million | $-70.37 Million | -2.381x | -2.43% |
| 2024-12-31 | $51.57 Million | $-119.89 Million | -2.325x | -307.31% |
| 2023-12-31 | $169.24 Million | $-96.59 Million | -0.571x | +0.75% |
| 2022-12-31 | $108.54 Million | $-62.42 Million | -0.575x | -190.12% |
| 2021-12-31 | $178.78 Million | $-35.44 Million | -0.198x | +77.02% |
| 2020-12-31 | $5.17 Million | $-4.46 Million | -0.863x | -101.42% |
| 2019-12-31 | $-21.00K | $-1.28 Million | 60.905x | -- |
About Biomea Fusion Inc
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase I… Read more